NRC — National Research Income Statement
0.000.00%
- $244.26m
- $302.73m
- $143.06m
- 86
- 72
- 26
- 65
Annual income statement for National Research, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 133 | 148 | 152 | 149 | 143 |
Cost of Revenue | |||||
Gross Profit | 84.1 | 95.6 | 94.5 | 92.6 | 86.1 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 90.6 | 97.7 | 105 | 109 | 108 |
Operating Profit | 42.7 | 50.3 | 46.5 | 40 | 35.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 41.5 | 48.6 | 42.8 | 40 | 32.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 37.3 | 37.5 | 31.8 | 31 | 24.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 37.3 | 37.5 | 31.8 | 31 | 24.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 37.2 | 37.4 | 31.8 | 31 | 24.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.43 | 1.47 | 1.68 | 1.26 | 1.05 |
Dividends per Share | |||||
Special Dividends per Share |